Supplemental Table 1 (Patient Demographics); Supplemental Table 2 (Association of ORR with Rash and Vitiligo) from Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Abstract

<p>Supplemental Table 1: Detailed patient characteristics of each cohort, including age, gender, race, disease stage, whether CNS disease was present, and what dose of nivolumab and/or vaccine was allocated. Supplemental Table 2: The relationship of overall response rate (ORR, PR + CR vs SD + PD) to vitiligo and rash. The authors found a statistically significant relationship between ORR and rash (p=0.03) and vitiligo (p=0.009).</p>